{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:07:50Z","timestamp":1778728070049,"version":"3.51.4"},"reference-count":122,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["202297"],"award-info":[{"award-number":["202297"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ucl.2026.02.012","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:50:28Z","timestamp":1773319828000},"page":"303-315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent Advances in Understanding the Biology of Castration-Resistant Prostate Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"David","family":"Llu\u00eds","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanli","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep Maria","family":"Piulats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Heras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Aytes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Kruithof de Julio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ucl.2026.02.012_bib1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41391-020-00308-x","article-title":"Clinical implications of genomic alterations in metastatic prostate cancer","volume":"24","author":"Sumiyoshi","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7406","key":"10.1016\/j.ucl.2026.02.012_bib2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ucl.2026.02.012_bib3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pharmthera.2013.07.003","article-title":"Androgen receptors in hormone-dependent and castration-resistant prostate cancer","volume":"140","author":"Shafi","year":"2013","journal-title":"Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.ucl.2026.02.012_bib4","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/2159-8290.CD-13-0142","article-title":"An F876l mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (Enzalutamide). Article","volume":"3","author":"Korpal","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ucl.2026.02.012_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.eururo.2017.08.012","article-title":"Moving towards precision urologic oncology: targeting enzalutamide-resistant prostate cancer and mutated forms of the androgen receptor using the novel inhibitor darolutamide (ODM-201)","volume":"73","author":"Borgmann","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.02.012_bib6","doi-asserted-by":"crossref","first-page":"E4473","DOI":"10.1073\/pnas.1802354115","article-title":"Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer","volume":"115","author":"Lee","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ucl.2026.02.012_bib7","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1074\/jbc.M109.039958","article-title":"Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H","volume":"285","author":"van de Wijngaart","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ucl.2026.02.012_bib8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/pros.22919","article-title":"18F-RB390: innovative ligand for imaging the T877A androgen receptor mutant in prostate cancer via PET","volume":"75","author":"Bertolini","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.ucl.2026.02.012_bib9","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jsbmb.2008.04.009","article-title":"CAG repeat variation and N\/C terminal interactions in the T877A mutant androgen receptor","volume":"111","author":"Southwell","year":"2008","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.012_bib10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/pros.23945","article-title":"A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant ARF876L nuclear import and function","volume":"80","author":"Wu","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.ucl.2026.02.012_bib11","article-title":"A case of prostate cancer harboring androgen receptor T878A progesterone-responsive mutant emerging after abiraterone acetate treatment responding to darolutamide","volume":"6","author":"Varkaris","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"11","key":"10.1016\/j.ucl.2026.02.012_bib12","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.3390\/cancers13112563","article-title":"AR splicing variants and resistance to AR targeting agents","volume":"13","author":"Kanayama","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.012_bib13","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-08-3795","article-title":"A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth","volume":"69","author":"Guo","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2026.02.012_bib14","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.1038\/s41388-020-01479-6","article-title":"Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors","volume":"39","author":"Zhu","year":"2020","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.012_bib15","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1158\/1078-0432.CCR-18-0320","article-title":"Expression of AR-V7 and ARv(567es) in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY","volume":"25","author":"Tagawa","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ucl.2026.02.012_bib16","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","article-title":"Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer","volume":"2","author":"Scher","year":"2016","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.012_bib17","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.18632\/oncotarget.1802","article-title":"Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy","volume":"5","author":"Cao","year":"2014","journal-title":"Oncotarget"},{"issue":"18","key":"10.1016\/j.ucl.2026.02.012_bib18","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1158\/0008-5472.CAN-15-0381","article-title":"Androgen receptor splice variants dimerize to transactivate target genes","volume":"75","author":"Xu","year":"2015","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.012_bib19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00008571-200007000-00004","article-title":"Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II","volume":"10","author":"Makridakis","year":"2000","journal-title":"Pharmacogenetics"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.012_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030062","article-title":"Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors","volume":"7","author":"Mostaghel","year":"2012","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.ucl.2026.02.012_bib21","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1200\/JCO.2003.11.102","article-title":"Androgen receptor mutations in androgen-independent prostate cancer: cancer and leukemia group B study 9663","volume":"21","author":"Taplin","year":"2003","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.012_bib22","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","article-title":"Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade","volume":"155","author":"Arora","year":"2013","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.012_bib23","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ijc.22365","article-title":"Androgen receptor coregulators and their involvement in the development and progression of prostate cancer","volume":"120","author":"Chmelar","year":"2007","journal-title":"Int J Cancer"},{"issue":"14","key":"10.1016\/j.ucl.2026.02.012_bib24","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1158\/1078-0432.CCR-15-2309","article-title":"ErbB2 signaling increases androgen receptor expression in abiraterone-resistant prostate cancer","volume":"22","author":"Gao","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.012_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.path.2024.10.003","article-title":"Deciphering complexity: the molecular landscape of castration-resistant prostate cancer","volume":"18","author":"Fanelli","year":"2025","journal-title":"Surg Pathol Clin"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.012_bib26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ccell.2014.11.013","article-title":"A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer","volume":"27","author":"Vidal","year":"2015","journal-title":"Cancer Cell"},{"issue":"17","key":"10.1016\/j.ucl.2026.02.012_bib27","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1073\/pnas.1304502110","article-title":"Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 (SRC-3)\/nuclear receptor signaling","volume":"110","author":"Geng","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.012_bib28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4103\/aja202259","article-title":"FOXA1 in prostate cancer","volume":"25","author":"Dong","year":"2023","journal-title":"Asian J Androl"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.012_bib29","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.cell.2018.07.015","article-title":"Nuclear pores promote lethal prostate cancer by increasing POM121-Driven E2F1, MYC, and AR nuclear import","volume":"174","author":"Rodriguez-Bravo","year":"2018","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.012_bib30","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","article-title":"The long tail of oncogenic drivers in prostate cancer","volume":"50","author":"Armenia","year":"2018","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.012_bib31","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-18-0981","article-title":"Randomized phase II study evaluating AKT blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss","volume":"25","author":"de Bono","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.ucl.2026.02.012_bib32","doi-asserted-by":"crossref","first-page":"10290","DOI":"10.1158\/0008-5472.CAN-08-2038","article-title":"A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells","volume":"68","author":"Liu","year":"2008","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.012_bib33","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s12079-022-00702-1","article-title":"Targeting PI3K\/Akt signaling in prostate cancer therapy","volume":"17","author":"Hashemi","year":"2023","journal-title":"J Cell Commun Signal"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.012_bib34","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.3390\/ijms24032289","article-title":"Addressing the reciprocal crosstalk between the AR and the PI3K\/AKT\/mTOR signaling pathways for prostate cancer treatment","volume":"24","author":"Raith","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.012_bib35","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ucl.2026.02.012_bib36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/JCO.2018.36.6_suppl.57","article-title":"P53 as a predictor of clinical outcome in localized prostate cancer","volume":"36","author":"Mahon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ucl.2026.02.012_bib37","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1038\/sj.onc.1207346","article-title":"Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines","volume":"23","author":"Cronauer","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ucl.2026.02.012_bib38","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","article-title":"Targeting signaling pathways in prostate cancer: mechanisms and clinical trials","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct Targeted Ther"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.012_bib39","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/1078-0432.CCR-18-2068","article-title":"Rb1 heterogeneity in advanced metastatic castration-resistant prostate cancer","volume":"25","author":"Rodrigues","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.012_bib40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bulcan.2024.05.008","volume":"112","author":"Oudard","year":"2025","journal-title":"Bull Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.012_bib41","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc3181","article-title":"BRCA1 and BRCA2: different roles in a common pathway of genome protection","volume":"12","author":"Roy","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/j.ucl.2026.02.012_bib42","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen receptor signaling regulates DNA repair in prostate cancers","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ucl.2026.02.012_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102145","article-title":"Highlighting function of Wnt signalling in urological cancers: molecular interactions, therapeutic strategies, and (nano)strategies","volume":"50","author":"Hashemi","year":"2024","journal-title":"Transl Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.012_bib44","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3390\/cancers17050774","article-title":"Cyclin-dependent kinase inhibition in prostate cancer: past, present, and future","volume":"17","author":"Siskin","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.ucl.2026.02.012_bib45","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/0008-5472.CAN-20-3351","article-title":"Activated ALK cooperates with N-Myc via Wnt\/\u03b2-catenin signaling to induce neuroendocrine prostate cancer","volume":"81","author":"Unno","year":"2021","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.ucl.2026.02.012_bib46","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/0008-5472.CAN-21-1807","article-title":"Autocrine canonical Wnt signaling primes noncanonical signaling through ROR1 in metastatic castration-resistant prostate cancer","volume":"82","author":"Ma","year":"2022","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.012_bib47","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41467-018-04042-w","article-title":"Frizzled-8 integrates Wnt-11 and transforming growth factor-\u03b2 signaling in prostate cancer","volume":"9","author":"Murillo-Garz\u00f3n","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.ucl.2026.02.012_bib48","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.14263","article-title":"GPX2 predicts recurrence-free survival and triggers the Wnt\/\u03b2-catenin\/EMT pathway in prostate cancer","volume":"10","author":"Yang","year":"2022","journal-title":"PeerJ"},{"issue":"19","key":"10.1016\/j.ucl.2026.02.012_bib49","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1158\/0008-5472.CAN-13-0882","article-title":"ERG is a critical regulator of Wnt\/LEF1 signaling in prostate cancer","volume":"73","author":"Wu","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2026.02.012_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116816","article-title":"Activated Wnt\/\u03b2-Catenin signaling contributes to E3 ubiquitin ligase EDD-conferred docetaxel resistance in prostate cancer","volume":"254","author":"Bian","year":"2020","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.012_bib51","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12672-025-01972-y","article-title":"The molecular pathogenesis of SOX2 in prostate cancer","volume":"16","author":"Liu","year":"2025","journal-title":"Discov Oncol"},{"issue":"9","key":"10.1016\/j.ucl.2026.02.012_bib52","first-page":"3051","article-title":"Targeting AKT\/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model","volume":"118","author":"Kinkade","year":"2008","journal-title":"J Clin Investig"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.012_bib53","first-page":"3154","article-title":"CD147 promotes epithelial\u2013mesenchymal transition of prostate cancer cells via the Wnt\/\u03b2-catenin pathway","volume":"20","author":"Fang","year":"2020","journal-title":"Exp Ther Med"},{"issue":"13","key":"10.1016\/j.ucl.2026.02.012_bib54","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/pros.24042","article-title":"Cancer-driven IgG promotes the development of prostate cancer through the SOX2-CIgG pathway","volume":"80","author":"Qin","year":"2020","journal-title":"Prostate"},{"issue":"5748","key":"10.1016\/j.ucl.2026.02.012_bib55","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.012_bib56","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccr.2010.03.018","article-title":"An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression","volume":"17","author":"Yu","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ucl.2026.02.012_bib57","first-page":"5605","article-title":"The oncogenic transcription factor ERG represses the transcription of the tumour suppressor gene PTEN in prostate cancer cells","volume":"14","author":"Adamo","year":"2017","journal-title":"Oncol Lett"},{"issue":"23","key":"10.1016\/j.ucl.2026.02.012_bib58","doi-asserted-by":"crossref","first-page":"6524","DOI":"10.1158\/0008-5472.CAN-17-0686","article-title":"Loss of FOXO1 cooperates with TMPRSS2-ERG overexpression to promote prostate tumorigenesis and cell invasion","volume":"77","author":"Yang","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2026.02.012_bib59","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.molcel.2015.07.025","article-title":"Truncated ERG oncoproteins from TMPRSS2-ERG fusions are resistant to SPOP-mediated proteasome degradation","volume":"59","author":"An","year":"2015","journal-title":"Mol Cell"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.012_bib60","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.annonc.2020.02.002","article-title":"Epigenetic modulations and lineage plasticity in advanced prostate cancer","volume":"31","author":"Ge","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ucl.2026.02.012_bib61","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1038\/s41467-020-19328-1","article-title":"Role of specialized composition of SWI\/SNF complexes in prostate cancer lineage plasticity","volume":"11","author":"Cyrta","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ucl.2026.02.012_bib62","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41588-020-0648-8","article-title":"The DNA methylation landscape of advanced prostate cancer","volume":"52","author":"Zhao","year":"2020","journal-title":"Nat Genet"},{"issue":"13","key":"10.1016\/j.ucl.2026.02.012_bib63","first-page":"3623","article-title":"Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer","volume":"60","author":"Kinoshita","year":"2000","journal-title":"Cancer Res"},{"issue":"17","key":"10.1016\/j.ucl.2026.02.012_bib64","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1128\/MCB.00235-10","article-title":"Opposing roles of Dnmt1 in early- and late-stage murine prostate cancer","volume":"30","author":"Kinney","year":"2010","journal-title":"Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.012_bib65","article-title":"Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy","volume":"15","author":"Wang","year":"2020"},{"key":"10.1016\/j.ucl.2026.02.012_bib66","doi-asserted-by":"crossref","first-page":"8219","DOI":"10.1038\/ncomms9219","article-title":"TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression","volume":"6","author":"Takayama","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.ucl.2026.02.012_bib67","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1158\/0008-5472.CAN-17-0496","article-title":"LSD1-mediated epigenetic reprogramming drives CENPE expression and prostate cancer progression","volume":"77","author":"Liang","year":"2017","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.ucl.2026.02.012_bib68","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/s41388-019-1116-8","article-title":"Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer","volume":"39","author":"Sara\u00e7","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.ucl.2026.02.012_bib69","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1038\/s41467-018-07511-4","article-title":"NSD2 is a conserved driver of metastatic prostate cancer progression","volume":"9","author":"Aytes","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.ucl.2026.02.012_bib70","doi-asserted-by":"crossref","first-page":"E4584","DOI":"10.1073\/pnas.1802415115","article-title":"Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells","volume":"115","author":"Fan","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ucl.2026.02.012_bib71","doi-asserted-by":"crossref","first-page":"26137","DOI":"10.18632\/oncotarget.8433","article-title":"REST reduction is essential for hypoxiainduced neuroendocrine differentiation of prostate cancer cells by activating autophagy signaling","volume":"7","author":"Lin","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ucl.2026.02.012_bib72","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.ucl.2026.02.012_bib73","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ucl.2026.02.012_bib74","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12943","article-title":"Bmi1 marks distinct castrationresistant luminal progenitor cells competent for prostate regeneration and tumour initiation","volume":"7","author":"Yoo","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.ucl.2026.02.012_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1269233","article-title":"Unlocking the role of non-coding RNAs in prostate cancer progression: exploring the interplay with the Wnt signaling pathway","volume":"14","author":"Bu","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ucl.2026.02.012_bib76","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrc1840","article-title":"Oncomirs\u2014microRNAs with a role in cancer","volume":"6","author":"Esquela-Kerscher","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ucl.2026.02.012_bib77","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrclinonc.2011.76","article-title":"MicroRNAs in body fluids\u2013the mix of hormones and biomarkers","volume":"8","author":"Cortez","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ucl.2026.02.012_bib78","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.juro.2011.11.082","article-title":"miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer","volume":"187","author":"Li","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2026.02.012_bib79","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1038\/onc.2011.624","article-title":"Androgenregulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer","volume":"31","author":"Jalava","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.ucl.2026.02.012_bib80","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.molcel.2007.05.010","article-title":"Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis","volume":"26","author":"Chang","year":"2007","journal-title":"Mol Cell"},{"key":"10.1016\/j.ucl.2026.02.012_bib81","doi-asserted-by":"crossref","first-page":"37993","DOI":"10.18632\/oncotarget.9366","article-title":"The tumor suppressive miR200b subfamily is an ERG target gene in human prostate tumors","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ucl.2026.02.012_bib82","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1756-8722-5-9","article-title":"Recent updates on the role of microRNAs in prostate cancer","volume":"5","author":"Hassan","year":"2012","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ucl.2026.02.012_bib83","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.3892\/ijo.2014.2363","article-title":"Linc00963: a novel, long non-coding RNA involved in the transition of prostate cancer from androgen-dependence to androgen-independence","volume":"44","author":"Wang","year":"2014","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ucl.2026.02.012_bib84","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1158\/1535-7163.MCT-19-0095","article-title":"LncRNA CCAT1 promotes prostate cancer cell proliferation by interacting with DDX5 and MIR-28-5P","volume":"18","author":"You","year":"2019","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.ucl.2026.02.012_bib85","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.molcel.2023.05.017","article-title":"Minor intron splicing is critical for survival of lethal prostate cancer","volume":"83","author":"Augspach","year":"2023","journal-title":"Mol Cell"},{"key":"10.1016\/j.ucl.2026.02.012_bib86","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.celrep.2017.12.081","article-title":"Loss of an androgen-inactivating and isoform-specific HSD17B4 splice form enables emergence of castration-resistant prostate cancer","volume":"22","author":"Ko","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.ucl.2026.02.012_bib87","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/1541-7786.MCR-19-0415","article-title":"A novel FGFR3 splice variant preferentially expressed in African American prostate cancer drives aggressive phenotypes and docetaxel resistance","volume":"17","author":"Olender","year":"2019","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ucl.2026.02.012_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2019.11.008","article-title":"Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer","volume":"51","author":"Jim\u00e9nez-Vacas","year":"2020","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.012_bib89","first-page":"180","article-title":"Role of prostate and bone stromal cells on prostate cancer progression","volume":"10","author":"Karkampouna","year":"2022","journal-title":"Am J Clin Exp Urol"},{"key":"10.1016\/j.ucl.2026.02.012_bib90","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.cell.2007.08.025","article-title":"Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment","volume":"131","author":"Sacchetti","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.ucl.2026.02.012_bib91","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1158\/0008-5472.CAN-09-2984","article-title":"Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model","volume":"70","author":"Terada","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2026.02.012_bib92","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/1878-0261.12327","article-title":"Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration","volume":"12","author":"Cioni","year":"2018","journal-title":"Mol Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.012_bib93","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1159\/000541881","article-title":"The immune microenvironment in prostate cancer: a comprehensive review","volume":"103","author":"Novysedlak","year":"2025","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.012_bib94","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/modpathol.2012.164","article-title":"CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer","volume":"26","author":"Davidsson","year":"2013","journal-title":"Mod Pathol"},{"issue":"14","key":"10.1016\/j.ucl.2026.02.012_bib95","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/pros.23890","article-title":"Increased infiltration of CCR4-positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis","volume":"79","author":"Watanabe","year":"2019","journal-title":"Prostate"},{"issue":"10","key":"10.1016\/j.ucl.2026.02.012_bib96","doi-asserted-by":"crossref","first-page":"845","DOI":"10.5306\/wjco.v12.i10.845","article-title":"Relationship between Th17 immune response and cancer","volume":"12","author":"Marques","year":"2021","journal-title":"World J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ucl.2026.02.012_bib97","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"41","key":"10.1016\/j.ucl.2026.02.012_bib98","doi-asserted-by":"crossref","first-page":"14776","DOI":"10.1073\/pnas.1416498111","article-title":"Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts","volume":"111","author":"Ammirante","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.012_bib99","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/pros.24315","article-title":"Multiplex immunohistochemical phenotyping of T cells in primary prostate cancer","volume":"82","author":"Ozbek","year":"2022","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.012_bib100","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.trecan.2018.03.010","article-title":"B7-H3 in cancer- beyond immune regulation","volume":"4","author":"Flem-Karlsen","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ucl.2026.02.012_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.ucl.2026.02.012_bib102","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in cancer: from biology to therapy","volume":"21","author":"Briukhovetska","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/j.ucl.2026.02.012_bib103","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00262-015-1752-y","article-title":"Dysfunction of PSA-specific CD8+Tcellsinprostatecancer patients correlates with CD38 and Tim-3 expression","volume":"64","author":"Japp","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ucl.2026.02.012_bib104","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ajur.2018.11.001","article-title":"Prostate tumor neuroendocrine differentiation via EMT: the road less traveled","volume":"6","author":"Dicken","year":"2019","journal-title":"Asian J Urol"},{"key":"10.1016\/j.ucl.2026.02.012_bib105","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1038\/sj.onc.1208429","article-title":"DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells","volume":"24","author":"Eger","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ucl.2026.02.012_bib106","first-page":"1625","article-title":"Loss of expression of transforming growth factor-\u03b2 receptors is associated with poor prognosis in prostate cancer patients","volume":"4","author":"Kim","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2026.02.012_bib107","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.200611146","article-title":"Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway","volume":"178","author":"Lamouille","year":"2007","journal-title":"J Cell Biol"},{"key":"10.1016\/j.ucl.2026.02.012_bib108","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s43018-022-00431-9","article-title":"Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance","volume":"3","author":"Deng","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ucl.2026.02.012_bib109","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/1535-7163.MCT-11-0289","article-title":"Identification of docetaxel resistance genes in castration-resistant prostate cancer","volume":"11","author":"Mar\u00edn-Aguilera","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ucl.2026.02.012_bib110","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/path.2205","article-title":"Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer","volume":"213","author":"Sahadevan","year":"2007","journal-title":"J Pathol"},{"key":"10.1016\/j.ucl.2026.02.012_bib111","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.3390\/ijms21134786","article-title":"Hypoxia promotes prostate cancer aggressiveness by upregulating EMT-activator Zeb1 and SK3 channel expression","volume":"21","author":"Bery","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ucl.2026.02.012_bib112","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.bbadis.2018.02.016","article-title":"Androgen deprivation therapy-induced epithelial-mesenchymal transition of prostate cancer through downregulating SPDEF and activating CCL2","volume":"1864","author":"Tsai","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.ucl.2026.02.012_bib113","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/onc.2009.322","article-title":"Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression","volume":"29","author":"Shiota","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ucl.2026.02.012_bib114","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1677\/ERC-10-0015","article-title":"N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer","volume":"17","author":"Jennbacken","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ucl.2026.02.012_bib115","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jcb.24948","article-title":"The presence of androgen receptor elements regulates ZEB1 expression in the absence of androgen receptor","volume":"116","author":"Mooney","year":"2015","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.ucl.2026.02.012_bib116","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12964-019-0410-y","article-title":"Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling","volume":"17","author":"Nath","year":"2019","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.ucl.2026.02.012_bib117","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.47678","article-title":"Androgen-regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer","volume":"8","author":"Munkley","year":"2019","journal-title":"eLife"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.012_bib118","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.012_bib119","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41392-023-01606-1","article-title":"Targeting ferroptosis opens new avenues for the development of novel therapeutics","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"13","key":"10.1016\/j.ucl.2026.02.012_bib120","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1016\/j.cell.2023.05.003","article-title":"Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones","volume":"186","author":"Liang","year":"2023","journal-title":"Cell"},{"issue":"49","key":"10.1016\/j.ucl.2026.02.012_bib121","doi-asserted-by":"crossref","first-page":"31189","DOI":"10.1073\/pnas.2017152117","article-title":"Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis","volume":"117","author":"Yi","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.012_bib122","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1158\/0008-5472.CAN-20-3477","article-title":"Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer","volume":"81","author":"Ghoochani","year":"2021","journal-title":"Cancer Res"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T02:15:33Z","timestamp":1778724933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":122,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0094014326000121"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.02.012","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent Advances in Understanding the Biology of Castration-Resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}